Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) and has been widely used in EGFR mutant advanced NSCLC patients 36 and advanced pancreatic cancer patients 37. This evidence concerns the gene EGFR and pancreatic neoplasm.